IMVT — Immunovant, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1764013 ·
Last close
$33.30
Market Cap
$6.88B
52W High
$45.42
52W Low
$15.56
ADV30
1,391,873
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -160,323,000 | -153,224,000 | 852,490,000 | 797,798,000 | 117,102,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -114,362,000 | -110,635,000 | 1,052,392,000 | 994,525,000 | 66,257,000 |
| Sep 2025 | 0 | — | -131,762,000 | -126,502,000 | 582,959,000 | 521,870,000 | 63,254,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-414,304,000
Investing CF
$-8,000
Financing CF
$612,935,000
CapEx
$-381,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.82
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,898,353,000
Inventory
—
Receivables
$697,000
ST Investments
—
EBIT TTM
$-566,001,000
Pretax Income TTM
$-538,915,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -532,902,000 | -505,606,000 | 957,014,000 | 104,422,000 | 852,592,000 | -407,310,000 |
| Mar 2025 | 0 | -438,152,000 | -413,840,000 | 776,222,000 | 68,775,000 | 707,447,000 | -375,874,000 |
| Mar 2024 | 0 | -270,209,000 | -259,336,000 | 666,365,000 | 48,608,000 | 617,757,000 | -214,227,000 |
| Mar 2023 | 0 | -208,276,000 | -210,960,000 | 405,838,000 | 43,344,000 | 362,494,000 | -188,193,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-267,152,000
OpCashFlow TTM
$0
Assets (Latest)
$776,222,000
Forward EPS
$-2.75
Max Pain — expiry 2026-12-18
max pain strike: $30.00 · spot: $33.49 · call oi: 8,952 · put oi: 278
Expected Move to 2026-12-18:
±$16.90
(50.46%) —
implied range
$16.59 –
$50.39
· ATM straddle on $32.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | $5.95B | $67.15 | — |
| SRRK | Scholar Rock Holding Corp | $5.92B | $48.63 | — |
| PCVX | Vaxcyte, Inc. | $8.36B | $56.21 | — |
| IBRX | ImmunityBio, Inc. | $8.95B | $8.44 | — |
| CRSP | CRISPR Therapeutics AG | $5.24B | $54.23 | — |
News headlines (Yahoo Finance, 1h cache)
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
2026-09-27 14:40 · Yahoo
Lilly’s latest China drug deal; Immunovant’s setback in lupus
2026-09-24 14:14 · Yahoo
Roivant reports top-line data from IMVT-1402 CLE trial
2026-09-24 09:32 · Yahoo
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
2026-09-23 17:44 · Yahoo
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
2026-09-23 12:32 · Yahoo
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
2026-09-23 12:12 · Yahoo
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint
2026-09-23 12:10 · Yahoo
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
2026-09-23 11:00 · Yahoo
Immunovant (IMVT) Stock Looks Expensive Based On Its Book Value
2026-09-15 01:15 · Yahoo
Is Immunovant (IMVT) Undervalued After Its Pullback to $37.36?
2026-09-14 21:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.